Journal ArticleDOI
Glycaemic variabilities: Key questions in pursuit of clarity.
TLDR
In this article, the authors considered that the within-subject variability of HbA1c calculated from consecutive determinations of HBA1c at regular time-intervals could be the most relevant index for assessing the long-term variability with a threshold value of 5% (%CV ǫ=ǫSD) to separate stability from lability.About:
This article is published in Diabetes & Metabolism.The article was published on 2021-09-18. It has received 8 citations till now.read more
Citations
More filters
Journal ArticleDOI
Metabolic modulation of synaptic failure and thalamocortical hypersynchronization with preserved consciousness in Glut1 deficiency
Karthik Rajasekaran,Qian Ma,Levi B. Good,Gauri Kathote,Vikram Jakkamsetti,Peiying Liu,Adrian Avila,Sharon Primeaux,Julio Enciso Alva,Kia H. Markussen,Isaac Marin-Valencia,Deepa Sirsi,Peter M. S. Hacker,Matthew S. Gentry,Jianzhong Su,Hanzhang Lu,Juan M. Pascual +16 more
TL;DR: Electroencephalography in G1D individuals revealed nutrition time-dependent seizure oscillations often associated with preserved volition despite electrographic generalization and uniform average oscillation duration and periodicity, suggesting increased facilitation of an underlying neural loop circuit.
Journal ArticleDOI
Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis
TL;DR: It is indicated that GLP-1 RAs have relatively high efficacy in terms of HbA1c and MAGE reduction when compared with other hypoglycemic agents and can thus have clinical application.
Journal ArticleDOI
Red blood cells as glucose carriers to the human brain: Modulation of cerebral activity by erythrocyte exchange transfusion in Glut1 deficiency (G1D)
TL;DR: In this article , the authors proposed a nearly direct pathway for metabolic substrate transfer to neural cells that complements the better characterized plasma to endothelium transfer, which was further substantiated by in vitro measurement of direct erythrocyte to endothelial cell glucose flux.
Journal ArticleDOI
Higher HbA1c variability is associated with increased arterial stiffness in individuals with type 1 diabetes
TL;DR: In this article , the authors investigated whether an association exists between arterial stiffness and long-term glycaemic variability in individuals with Type 1 diabetes, and they found that HbA1c-ARV was associated with carotid-femoral pulse wave velocity (cfPWV) and augmentation index (AIx).
Journal ArticleDOI
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
TL;DR: In this article , the authors used the coefficient of variation for glucose (%CV) as the reference to assess the within-day glucose variability and a cutoff of 36 % has been acknowledged as the most appropriate threshold to separate stable from labile glycemic control.
References
More filters
Journal ArticleDOI
Biochemistry and molecular cell biology of diabetic complications
TL;DR: This integrating paradigm provides a new conceptual framework for future research and drug discovery in diabetes-specific microvascular disease and seems to reflect a single hyperglycaemia-induced process of overproduction of superoxide by the mitochondrial electron-transport chain.
Journal ArticleDOI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman,Christoph Wanner,John M. Lachin,David Fitchett,Erich Bluhmki,Stefan Hantel,Michaela Mattheus,Theresa Devins,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +11 more
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more
TL;DR: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.